Clinical Trial Update: Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)

View source ↗

Summary

An observational trial evaluating fenofibrate (Lipilfen Capsule) for the incidence of major adverse cardiovascular events and safety in metabolic syndrome has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Lipilfen Capsule (fenofibrate)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Metabolic Syndrome | Status: WITHDRAWN